Lifeward Partners with AbilityLab to Streamline Exoskeleton Access
Event summary
- Lifeward is collaborating with Shirley Ryan AbilityLab to offer dedicated clinic days for evaluation and trial of the ReWalk Personal Exoskeleton, starting in Q2 2026.
- The clinics aim to accelerate adoption of the ReWalk exoskeleton for individuals with spinal cord injury (SCI).
- Shirley Ryan AbilityLab will provide clinical evaluation, training, and support throughout the process.
- This marks Lifeward’s first collaboration with a nationally recognized rehabilitation research hospital.
The big picture
Lifeward's collaboration with Shirley Ryan AbilityLab represents a strategic shift towards integrating its exoskeleton technology within established clinical workflows. This move addresses a key barrier to adoption – the complexity of evaluation and fitting – and positions Lifeward to capitalize on the growing demand for assistive robotics in rehabilitation. The partnership also highlights the increasing importance of specialized clinics in driving adoption of complex medical devices, a trend likely to accelerate as the market matures.
What we're watching
- Adoption Rate
- The success of this collaboration hinges on Lifeward's ability to convert evaluations into sales; a significant drop-off between trial and purchase would signal underlying issues with product suitability or pricing.
- Reimbursement
- Third-party payor coverage, particularly from CMS, remains a critical factor for widespread adoption; any changes in reimbursement policies could significantly impact Lifeward's revenue projections.
- Competitive Landscape
- The partnership may attract other exoskeleton manufacturers to seek similar collaborations, intensifying competition and potentially impacting Lifeward's market share and pricing power.
Related topics